ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms and Ichor ...
NEW YORK, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI) today announced the successful completion of the second dose cohort (single dose of 30 mg administered orally) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results